ArticleInternational journal of ophthalmology2016
Therapeutic effects of mesenchymal stem cells administered at later phase of recurrent experimental autoimmune uveitis.
Article in International journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Mesenchymal stem cell based therapies for uveitis: a systematic review of preclinical studies.Eye (London, England) · 2024Pooled it
- Role of stem cells in ocular diseases: Progress and challenges.Journal of biomedical research · 2026Article
- Review
- Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.Progress in retinal and eye research · 2021Review
- Potential therapeutic applications of mesenchymal stem cells for the treatment of eye diseases.World journal of stem cells · 2021Review
- Preliminary studies of constructing a tissue-engineered lamellar corneal graft by culturing mesenchymal stem cells onto decellularized corneal matrix.International journal of ophthalmology · 2021Article
- Human umbilical cord-derived mesenchymal stem cells treatment for refractory uveitis: a case series.International journal of ophthalmology · 2021Article
- Article
- Antioxidant and Biological Properties of Mesenchymal Cells Used for Therapy in Retinitis Pigmentosa.Antioxidants (Basel, Switzerland) · 2020Review
- Mesenchymal stem cell-derived extracellular vesicles as a new therapeutic strategy for ocular diseases.World journal of stem cells · 2020Review
- Stem Cell Surgery and Growth Factors in Retinitis Pigmentosa Patients: Pilot Study after Literature Review.Biomedicines · 2019Article
- Cytokine interplay among the diseased retina, inflammatory cells and mesenchymal stem cells - a clue to stem cell-based therapy.World journal of stem cells · 2019Review
- Metabolic profile analysis of free amino acids in experimental autoimmune uveoretinitis rat plasma.International journal of ophthalmology · 2019Article
- Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases.International journal of molecular sciences · 2017Review
- Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoimmune Uveitis.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo test the therapeutic effects of delayed treatment of mesenchymal stem cells (MSCs) in recurrent experimental autoimmune uveitis (rEAU).
methodsThe efficacy of different regimens of MSC administration in rEAU were tested by evaluation of clinical and pathological intraocular inflammation, as well as retinal structural and functional integrity using optical coherence tomography (OCT) and electroretinogram (ERG). The retinal sections were also immunostained with antibodies to glial fibrillary acidic protein (GFAP) and rhodopsin (RHO).
resultsDelayed treatment of MSCs effectively alleviated the severity of intraocular inflammation with relative intact of outer retinal structure and function. Moreover, double therapies with longer interval led to an even better clinical evaluation, as well as a trend of decrease in relapse and amelioration of retinal function. MSC therapies also effectively reduced GFAP expression and increased RHO expression in the retina.
conclusionMSC administration can effectively treat developed diseases of rEAU, and multiple therapies can provide additional therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.